GCG and fatty liver disease: Clinical prescription of glucagon-like peptide-1 (GLP-1) analogues take advantage of this imbalance by promoting Ang1–7 formation, reducing hepatic steatosis by enhancing carbohydrate metabolism and impairing hepatic gluconeogenesis [4,35].